MCID: CHR070
MIFTS: 46

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Categories: Neuronal diseases

Aliases & Classifications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards integrated aliases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

Name: Chronic Inflammatory Demyelinating Polyradiculoneuropathy 12 36 14
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 69
Polyradiculoneuropathy Chronic Inflammatory Demyelinating 51

Classifications:



External Ids:

Disease Ontology 12 DOID:5213
ICD10 32 G61.81
ICD9CM 34 357.81
MeSH 41 D020277
NCIt 46 C84636
SNOMED-CT 64 128209004 444728005
KEGG 36 H01527
UMLS 69 C0393819

Summaries for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards based summary : Chronic Inflammatory Demyelinating Polyradiculoneuropathy, also known as polyradiculoneuropathy, chronic inflammatory demyelinating, is related to alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity and hereditary neuropathy with liability to pressure palsy. An important gene associated with Chronic Inflammatory Demyelinating Polyradiculoneuropathy is MPZ (Myelin Protein Zero), and among its related pathways/superpathways are Allograft rejection and NF-kappaB Signaling. The drugs Antibodies and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, t cells and skin, and related phenotypes are cellular and hematopoietic system

Related Diseases for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
# Related Disease Score Top Affiliating Genes
1 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.6 IFNG IL17A
2 hereditary neuropathy with liability to pressure palsy 30.6 MPZ PMP22
3 neuropathy, hereditary, with liability to pressure palsies 30.5 MPZ PMP22
4 chronic graft versus host disease 30.4 ALB IFNG
5 demyelinating polyneuropathy 30.3 ALB PMP22
6 polyneuropathy 30.2 MBP MPZ PMP22
7 optic neuritis 30.1 MBP MPZ
8 hereditary neuropathies 30.0 MBP MPZ PMP22
9 neuritis 29.8 IFNG MBP MPZ PMP22
10 autoimmune disease 29.7 IFNG IL17A MBP
11 systemic lupus erythematosus 29.6 ALB IFNB1 IFNG IL17A
12 polyradiculoneuropathy 29.6 ALB CXCR4 IFNG IL17A MBP MPZ
13 guillain-barre syndrome 29.6 ALB MBP MPZ PMP22
14 multiple sclerosis 29.4 IFNB1 IFNG IL17A MBP MPZ
15 chronic inflammatory demyelinating polyneuropathy 12.0
16 chronic inflammatory demyelinating polyneuritis 11.3
17 charcot-marie-tooth neuropathy type 1 10.5 MPZ PMP22
18 foot drop 10.4 MPZ PMP22
19 charcot-marie-tooth disease, demyelinating, type 1f 10.4 MPZ PMP22
20 charcot-marie-tooth disease, demyelinating, type 1b 10.4 MPZ PMP22
21 charcot-marie-tooth disease, axonal, type 2b 10.4 MPZ PMP22
22 roussy-levy hereditary areflexic dystasia 10.4 MPZ PMP22
23 motor peripheral neuropathy 10.4 MPZ PMP22
24 charcot-marie-tooth disease, demyelinating, type 1a 10.4 MPZ PMP22
25 neuropathy 10.4
26 charcot-marie-tooth disease, demyelinating, type 1d 10.4 MPZ PMP22
27 tuberculous peritonitis 10.3 ALB IFNG
28 charcot-marie-tooth disease, demyelinating, type 1c 10.3 MPZ PMP22
29 trichosporonosis 10.3 IFNG IL17A
30 fascioliasis 10.3 ALB IFNG
31 hypersplenism 10.3 ALB IFNG
32 myositis fibrosa 10.3 IFNG IL17A
33 hemorrhagic fever 10.3 ALB IFNG
34 niemann-pick disease, type a 10.3 MBP MPZ
35 central nervous system vasculitis 10.3 IFNG IL17A
36 hepatitis e 10.3 ALB IFNG
37 charcot-marie-tooth disease and deafness 10.3 MPZ PMP22
38 aspiration pneumonia 10.3 ALB IL17A
39 multifocal motor neuropathy 10.3
40 primary systemic mycosis 10.3 IFNG IL17A
41 mucinoses 10.3 IFNB1 IFNG
42 paranasal sinus disease 10.2 IFNG IL17A
43 lupus erythematosus 10.2
44 transient arthritis 10.2 ALB MBP
45 opportunistic mycosis 10.2 IFNG IL17A
46 septicemic plague 10.2 IFNB1 IL17A
47 echinococcosis 10.2 IFNG IL17A
48 transverse myelitis 10.2 IL17A MBP
49 diabetes mellitus 10.2
50 cervicitis 10.2

Graphical network of the top 20 diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:



Diseases related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Symptoms & Phenotypes for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MGI Mouse Phenotypes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.95 PMP22 IFNG ALB MBP CXCL12 MPZ
2 hematopoietic system MP:0005397 9.91 IFNB1 IFNG IL17A MBP CXCL12 MPZ
3 immune system MP:0005387 9.87 IFNB1 IFNG IL17A MBP CXCL12 MPZ
4 mortality/aging MP:0010768 9.86 IFNG IL17A ALB MBP CXCL12 MPZ
5 muscle MP:0005369 9.55 CXCR4 PMP22 IFNG ALB CXCL12
6 nervous system MP:0003631 9.5 PMP22 IFNB1 IFNG MBP CXCL12 MPZ
7 reproductive system MP:0005389 9.1 IFNG MBP CXCL12 MPZ CXCR4 PMP22

Drugs & Therapeutics for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Drugs for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 4,Phase 3,Phase 2,Phase 1
2 gamma-Globulins Phase 4,Phase 3,Phase 2
3 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1
4 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2
5 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2
6
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
7
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
8
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
9 tannic acid Approved, Nutraceutical Phase 3
10 Fingolimod Hydrochloride Phase 3
11 Immunosuppressive Agents Phase 3,Phase 2
12 Anti-Inflammatory Agents Phase 3
13 Antineoplastic Agents, Hormonal Phase 3
14 glucocorticoids Phase 3
15 Hormone Antagonists Phase 3,Phase 2
16 Hormones Phase 3,Phase 2
17 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
18 Pharmaceutical Solutions Phase 3,Phase 2
19
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
21 Adjuvants, Immunologic Phase 2
22 Anti-Infective Agents Phase 2
23 Antiviral Agents Phase 2
24 Interferon-beta Phase 2
25 interferons Phase 2
26 Antioxidants Phase 2
27 Micronutrients Phase 2
28 Protective Agents Phase 2
29 Thioctic Acid Phase 2
30 Trace Elements Phase 2
31 Vitamin B Complex Phase 2
32 Vitamins Phase 2
33 Alpha-lipoic Acid Nutraceutical Phase 2
34 Folate Nutraceutical Phase 2
35 Vitamin B9 Nutraceutical Phase 2

Interventional clinical trials:

(show all 42)

# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
3 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
4 Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Completed NCT01625182 Phase 3 Fingolimod;Placebo Comparator
5 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
6 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
7 Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Completed NCT02293460 Phase 3 I10E
8 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
9 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
10 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
11 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
12 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
13 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
14 Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Recruiting NCT02955355 Phase 3
15 Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Recruiting NCT02549170 Phase 3
16 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
17 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
18 Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Terminated NCT02317562 Phase 3 I10E
19 Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Terminated NCT01225276 Phase 2, Phase 3 NewGam 10%;Placebo;NewGam 10%;NewGam 10%
20 Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
21 Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT01017159 Phase 2 Subcutaneous immunoglobulin
22 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
23 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
24 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2
25 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2 MD1003
26 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
27 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
28 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
29 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
30 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
31 MRI in Diagnosing and Monitoring CIDP Completed NCT02017769
32 Study of CIDP Patients During IVIG Treatment Completed NCT00305266 intravenous gammaglobulin
33 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678
34 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
35 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
36 Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Recruiting NCT02629796
37 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Recruiting NCT02414490 Intravenous Immunoglobulin
38 Transcriptome Analysis of the Peripheral Blood in CIDP Recruiting NCT02404298 IVIg
39 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
40 Subcutaneous Immunoglobulin for CIDP Active, not recruiting NCT02465359 Immune Globulin Subcutaneous (Human)
41 Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin Not yet recruiting NCT02892890
42 Quantification of Nerve Stiffness in Neuropathies Not yet recruiting NCT03397303

Search NIH Clinical Center for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Genetic Tests for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Anatomical Context for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

MalaCards organs/tissues related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

38
Spinal Cord, T Cells, Skin, Brain, Tongue, Nk Cells, Thyroid

Publications for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Articles related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy:

(show top 50) (show all 325)
# Title Authors Year
1
Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29360221 )
2018
2
Nerve Ultrasound Predicts Treatment Response in Chronic Inflammatory Demyelinating Polyradiculoneuropathy-a Prospective Follow-Up. ( 29435815 )
2018
3
Parallel fluctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological findings in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249367 )
2018
4
A significant correlation between cauda equina conduction time and cerebrospinal fluid protein in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29249382 )
2018
5
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. ( 28481421 )
2017
6
Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews. ( 28084646 )
2017
7
Protocol of a dose response trial of IV immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (DRIP study). ( 29119642 )
2017
8
Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatment. ( 28382108 )
2017
9
Chronic inflammatory demyelinating polyradiculoneuropathy-causing myelopathy. ( 28786217 )
2017
10
Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29089585 )
2017
11
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. ( 29185258 )
2017
12
Maintenance IV immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy. ( 29092099 )
2017
13
Blink R1 latency utility in diagnosis and treatment assessment of polyradiculoneuropathy-organomegaly-endocrinopathy-monoclonal protein-skin changes and chronic inflammatory demyelinating polyradiculoneuropathy. ( 28646568 )
2017
14
Anti-NF155 chronic inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. ( 29145880 )
2017
15
Rituximab in refractory chronic inflammatory demyelinating polyradiculoneuropathy: report of four cases. ( 28337614 )
2017
16
ARTHUR ASBURY LECTURE: Chronic inflammatory demyelinating polyradiculoneuropathy: clinical aspects and new animal models of auto-immunity to nodal components. ( 29065233 )
2017
17
Chronic inflammatory demyelinating polyradiculoneuropathy and anesthesia: a case series. ( 28936613 )
2017
18
Multiple Sites Ultrasonography of Peripheral Nerves in Differentiating Charcot-Marie-Tooth Type 1A from Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 28522988 )
2017
19
Fibronectin connecting segment-1 peptide inhibits pathogenic leukocyte trafficking and inflammatory demyelination in experimental models of chronic inflammatory demyelinating polyradiculoneuropathy. ( 28215575 )
2017
20
Quality of life predictors in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29086018 )
2017
21
Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. ( 27781132 )
2016
22
A case of chronic inflammatory demyelinating polyradiculoneuropathy after treatment with pegylated interferon I+-2a in a patient with chronic hepatitis B virus infection. ( 27680223 )
2016
23
Improving the management of chronic inflammatory demyelinating polyradiculoneuropathy. ( 27230584 )
2016
24
Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets. ( 27838091 )
2016
25
A case of severe chronic inflammatory demyelinating polyradiculoneuropathy with monoclonal gammopathy of undetermined significance with alternating immunoglobulin class to IgM from IgA. ( 27580763 )
2016
26
Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand. ( 27113227 )
2016
27
Fatigue, Pain, Anxiety and Depression in Guillain-BarrAc Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 27077919 )
2016
28
Chronic inflammatory demyelinating polyradiculoneuropathy occurring after autologous haematopoietic stem cell transplantation for multiple sclerosis. ( 28607734 )
2016
29
A case of a 17-year-old male with neurofascin-155 antibody-positive chronic inflammatory demyelinating polyradiculoneuropathy presenting with tremor and ataxia. ( 27580761 )
2016
30
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): Clinical Features, Diagnosis, and Current Treatment Strategies. ( 27902997 )
2016
31
Transcriptome Analysis of Peripheral Blood in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients Identifies TNFR1 and TLR Pathways in the IVIg Response. ( 27175635 )
2016
32
IgG4 anti-neurofascin155 antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: Clinical significance and diagnostic utility of a conventional assay. ( 27852440 )
2016
33
Stance Postural Strategies in Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 26977594 )
2016
34
Cerebral infarction following subcutaneous immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy. ( 26873805 )
2016
35
Multiple Myeloma Associated Chronic Inflammatory Demyelinating Polyradiculoneuropathy: The Importance of Continued Surveillance. ( 28070468 )
2016
36
Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 27211560 )
2016
37
Intravenous Immunoglobulins Lower Inflammatory Gene Expression in Skin Biopsies of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. ( 27286956 )
2016
38
Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-BarrAc syndrome: a case report. ( 27380808 )
2016
39
Motor unit number index (MUNIX): Is it relevant in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)? ( 26750580 )
2016
40
Peripheral Nerve Ultrasonography in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: Correlations with Clinical and Neurophysiological Data. ( 27313890 )
2016
41
Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyradiculoneuropathy, a time to start and a time to stop. ( 27241239 )
2016
42
A Bodybuilder With Weak Hands and Feet: Corticosteroid-Responsive Pure Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy Following Anabolic Steroid Use. ( 27438336 )
2016
43
Which criteria for research in chronic inflammatory demyelinating polyradiculoneuropathy? an analysis of current practice. ( 25354388 )
2015
44
Chronic inflammatory demyelinating polyradiculoneuropathy with cranial nerves hypertrophy, thyroid-related orbitopathy and IgG monoclonal gammopathy: a case report. ( 25647292 )
2015
45
Triple-stimulation technique improves the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy. ( 25571892 )
2015
46
Characteristic MRI features of chronic inflammatory demyelinating polyradiculoneuropathy. ( 25687202 )
2015
47
Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy. ( 25561247 )
2015
48
Relapse with Dysphagia in a Case of Chronic Inflammatory Demyelinating Polyradiculoneuropathy. ( 26179538 )
2015
49
Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice. ( 26437234 )
2015
50
Update on the treatment of chronic inflammatory demyelinating polyradiculoneuropathy. ( 26203970 )
2015

Variations for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Expression for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Search GEO for disease gene expression data for Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Pathways for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

GO Terms for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Cellular components related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 9.13 ALB MBP MPZ
2 compact myelin GO:0043218 8.62 MBP PMP22

Biological processes related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.63 MBP MPZ PMP22
2 immune response GO:0006955 9.62 CXCL12 IFNG IL17A MBP
3 regulation of receptor activity GO:0010469 9.56 CXCL12 IFNB1 IFNG IL17A
4 cell death GO:0008219 9.48 IL17A PMP22
5 positive regulation of interleukin-6 secretion GO:2000778 9.43 IL17A MBP
6 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.4 IFNB1 IFNG
7 positive regulation of osteoclast differentiation GO:0045672 9.37 IFNG IL17A
8 positive regulation of interleukin-23 production GO:0032747 9.16 IFNG IL17A
9 myelination GO:0042552 9.13 MBP MPZ PMP22
10 response to virus GO:0009615 8.92 CXCL12 CXCR4 IFNB1 IFNG

Molecular functions related to Chronic Inflammatory Demyelinating Polyradiculoneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 CXCL12 IFNB1 IFNG IL17A

Sources for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....